NASDAQ
0.79USD
-0.02 (-2.17%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
22M
P/E
—
EPS
—
Beta
1.37
52W range
0.694-2.18
Day range
0.78–0.83
Open
0.81
Prev close
0.81
Volume
217.4K
Avg volume
816.5K
Dividend
0.00
IPO
2017-06-29
https://www.globenewswire.com/news-release/2026/08/14/3345214/28652/en/rein-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html · 8/14/2026+0.60
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
